Results 21 to 30 of about 20,748 (167)

Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis

Frontiers in Oncology, 2022
Herein, we report the first case presentation of paraneoplastic myelofibrosis associated with cancer. Paraneoplastic syndromes occur in some patients with thoracic malignancies; however, myelofibrosis is not commonly seen in non-small cell lung cancer ...
Lindsey Sloan, Lindsey Sloan, Rakhi P. Naik, Kavita Umrau, Rena Ruiyu Xian, Kristen A. Marrone, Khinh Ranh Voong   +6 more
doaj   +1 more source

Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up

Haematologica, 2014
Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima, Julia Turbiner Geyer, Christina S. Lee, Leonardo Boiocchi, Allison A. Imahiyerobo, Attilio Orazi, James B. Bussel   +6 more
doaj   +1 more source

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos, Juliana Corrêa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria de Lourdes Lopes Ferrari Chauffaille   +5 more
doaj   +1 more source

The Regulatory Role of Iron Transporter SLC39A13 in Liver Fibrosis

Advanced Science, EarlyView.
SLC39A13/ZIP13, a newly discovered intracellular iron transporter, delivers iron to the ER/Golgi to catalyze procollagen hydroxylation during collagen maturation. Here, we systematically characterize the cell type‐specific functions of ZIP13 across distinct hepatic cell populations, and identify hepatic stellate cell‐specific ZIP13 as a promising and ...
Shanshan Guo, Yalin Wang, Binyu Lu, Yu Zhang, David M. Frazer, Bing Zhou   +5 more
wiley   +1 more source

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

SAGE Open Medical Case Reports, 2013
Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine ...
Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski, Ramon V Tiu   +8 more
doaj   +1 more source

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

Srpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna, Peruničić-Jovanović Maja, Šefer Dijana, Bižić-Radulović Sandra, Soldatović Ivan, Todorović-Balint Milena   +5 more
doaj   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

Haematologica, 2014
Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville, Jérôme Rey, Raynier Devillier, Arnaud Guille, Rémi Gillet, José Adélaide, Véronique Gelsi-Boyer, Christine Arnoulet, Max Chaffanet, Marie-Joelle Mozziconacci, Norbert Vey, Daniel Birnbaum, Anne Murati   +12 more
doaj   +1 more source

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse

Clinical Case Reports, 2023
Key Clinical Message Here, we describe a patient with post‐transplant myelofibrosis with chronic graft‐versus‐host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD.
Barnali Srivastava, Christine Wolschke, Nico Gagelmann, Anita Badbaran, Nicolaus Kröger   +4 more
doaj   +1 more source

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

Haematologica, 2012
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, Hans Kreipe   +5 more
doaj   +1 more source